MedPath

Pyrazinamide

PYRAZINAMIDE Tablets, USP 500 mg

Approved
Approval ID

a8b7ba02-8509-475b-8a3b-39d205af3f1e

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Dec 6, 2022

Manufacturers
FDA

Macleods Pharmaceuticals Limited

DUNS: 862128535

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Pyrazinamide

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code33342-447
Application NumberANDA212541
Product Classification
M
Marketing Category
C73584
G
Generic Name
Pyrazinamide
Product Specifications
Route of AdministrationORAL
Effective DateDecember 6, 2022
FDA Product Classification

INGREDIENTS (7)

STARCH, CORNInactive
Code: O8232NY3SJ
Classification: IACT
POVIDONEInactive
Code: FZ989GH94E
Classification: IACT
PYRAZINAMIDEActive
Quantity: 500 mg in 1 1
Code: 2KNI5N06TI
Classification: ACTIB
TALCInactive
Code: 7SEV7J4R1U
Classification: IACT
MAGNESIUM STEARATEInactive
Code: 70097M6I30
Classification: IACT
SILICON DIOXIDEInactive
Code: ETJ7Z6XBU4
Classification: IACT
SODIUM STARCH GLYCOLATE TYPE A POTATOInactive
Code: 5856J3G2A2
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Pyrazinamide - FDA Drug Approval Details